Jose Gutierrez1, Farid Khasiyev2, Minghua Liu3, Janet T DeRosa3, Sarah E Tom4, Tatjana Rundek5, Ken Cheung6, Clinton B Wright7, Ralph L Sacco5, Mitchell S V Elkind4. 1. Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA. Electronic address: jg3233@cumc.columbia.edu. 2. Department of Neurology, Saint Louis University, Saint Louis, Missouri, USA. 3. Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA. 4. Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA. 5. Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA; Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. 6. Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA. 7. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide and confers a high risk of stroke recurrence, despite aggressive management of risk factors. OBJECTIVES: This study identified the role of risk factors and risk of vascular events in subjects with asymptomatic ICAS for improved risk stratification. METHODS: Stroke-free participants in the NOMAS (Northern Manhattan Study) trial, prospectively followed since 1993, underwent a brain magnetic resonance angiogram from 2003 to 2008. The study rated stenosis in 11 brain arteries as: 0: no stenosis; 1: <50% or luminal irregularities; 2: 50%-69%; and 3: ≥70% stenosis or flow gap. The study ascertained vascular events during the post-magnetic resonance imaging (MRI) period. Proportional odds regression quantified the association of pre-MRI exposures, and proportional hazard adjusted models were built to identify the risk of events in the post-MRI period. RESULTS: The included sample included 1,211 participants from NOMAS (mean age: 71 ± 9 years; 59% women; 65% Hispanic; 45% had any stenosis). Older age (OR: 1.02 per year; 95% CI: 1.01 to 1.04), hypertension duration (OR: 1.01 per year; 95% CI: 1.00 to 1.02), higher number of glucose-lowering drugs (OR: 1.64 per each medication; 95% CI: 1.24 to 2.15), and high-density lipoprotein (OR: 0.96 per mg/dL; 95% CI: 0.92 to 0.99) were associated with ICAS. The highest event risk was noted among participants with ICAS ≥70% (5.5% annual risk of vascular events; HR: 2.1; 95% CI:1.4 to 3.2; compared with those with no ICAS). CONCLUSIONS: ICAS is an imaging marker of established atherosclerotic disease in stroke-free subjects, and incidental diagnosis of ICAS should trigger a thorough assessment of vascular health.
BACKGROUND: Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide and confers a high risk of stroke recurrence, despite aggressive management of risk factors. OBJECTIVES: This study identified the role of risk factors and risk of vascular events in subjects with asymptomatic ICAS for improved risk stratification. METHODS: Stroke-free participants in the NOMAS (Northern Manhattan Study) trial, prospectively followed since 1993, underwent a brain magnetic resonance angiogram from 2003 to 2008. The study rated stenosis in 11 brain arteries as: 0: no stenosis; 1: <50% or luminal irregularities; 2: 50%-69%; and 3: ≥70% stenosis or flow gap. The study ascertained vascular events during the post-magnetic resonance imaging (MRI) period. Proportional odds regression quantified the association of pre-MRI exposures, and proportional hazard adjusted models were built to identify the risk of events in the post-MRI period. RESULTS: The included sample included 1,211 participants from NOMAS (mean age: 71 ± 9 years; 59% women; 65% Hispanic; 45% had any stenosis). Older age (OR: 1.02 per year; 95% CI: 1.01 to 1.04), hypertension duration (OR: 1.01 per year; 95% CI: 1.00 to 1.02), higher number of glucose-lowering drugs (OR: 1.64 per each medication; 95% CI: 1.24 to 2.15), and high-density lipoprotein (OR: 0.96 per mg/dL; 95% CI: 0.92 to 0.99) were associated with ICAS. The highest event risk was noted among participants with ICAS ≥70% (5.5% annual risk of vascular events; HR: 2.1; 95% CI:1.4 to 3.2; compared with those with no ICAS). CONCLUSIONS: ICAS is an imaging marker of established atherosclerotic disease in stroke-free subjects, and incidental diagnosis of ICAS should trigger a thorough assessment of vascular health.
Authors: Muhammad Fareed K Suri; Ye Qiao; Xiaoye Ma; Eliseo Guallar; Jincheng Zhou; Yiyi Zhang; Li Liu; Haitao Chu; Adnan I Qureshi; Alvaro Alonso; Aaron R Folsom; Bruce A Wasserman Journal: Stroke Date: 2016-04-07 Impact factor: 7.914
Authors: Jose Gutierrez; Sebastian Koch; Chuanhui Dong; Teresita Casanova; Royya Modir; Michael Katsnelson; Gustavo A Ortiz; Ralph L Sacco; Jose G Romano; Tatjana Rundek Journal: Neurol Sci Date: 2013-10-15 Impact factor: 3.307
Authors: Anna Planas-Ballvé; Ane Miren Crespo; Lorena Martín Aguilar; María Hernández-Pérez; Tamara Canento; Laura Dorado; María T Alzamora; Pere Torán; Guillem Pera; Laura Muñoz-Ortiz; Juan F Arenillas; María Castañón; Antoni Dávalos; Mónica Millán; Elena López-Cancio Journal: Atherosclerosis Date: 2019-01-29 Impact factor: 5.162
Authors: R L Sacco; B Boden-Albala; R Gan; X Chen; D E Kargman; S Shea; M C Paik; W A Hauser Journal: Am J Epidemiol Date: 1998-02-01 Impact factor: 4.897
Authors: Anastasios Chatzikonstantinou; Anne D Ebert; Stefan O Schoenberg; Michael G Hennerici; Thomas Henzler Journal: Int J Neurosci Date: 2014-09-30 Impact factor: 2.292
Authors: Mitchell S V Elkind; Nancy K Hills; Carol A Glaser; Warren D Lo; Catherine Amlie-Lefond; Nomazulu Dlamini; Rachel Kneen; Eldad A Hod; Max Wintermark; Gabrielle A deVeber; Heather J Fullerton Journal: Circulation Date: 2016-01-26 Impact factor: 29.690
Authors: Minghua Liu; Sanjeev Sariya; Farid Khasiyev; Giuseppe Tosto; Nicole D Dueker; Ying Kuen Cheung; Clinton B Wright; Ralph L Sacco; Tatjana Rundek; Mitchell S V Elkind; Jose Gutierrez Journal: J Neurol Sci Date: 2022-03-03 Impact factor: 4.553
Authors: Amol Mehta; Farid Khasiyev; Clinton B Wright; Tatjana Rundek; Ralph L Sacco; Mitchell S V Elkind; Jose Gutierrez Journal: Stroke Date: 2022-02-02 Impact factor: 10.170